The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Large Is The Compounding Chemotherapy Market Projected To Become By 2030 Based On Its 2026 Valuation?
The compounding chemotherapy market has experienced substantial expansion in recent years. Projections indicate it will increase from $6.11 billion in 2025 to $6.49 billion in 2026, with a compound annual growth rate (CAGR) of 6.2%. Historically, this growth was influenced by factors such as the limited availability of compounding technologies, the rising prevalence of cancer, the dependence on hospital-based compounding, an increasing awareness of cytotoxic drug safety, and the utilization of manual preparation methods.
The compounding chemotherapy market is anticipated to experience robust expansion in the coming years. By 2030, this market is projected to reach $8.2 billion, demonstrating a compound annual growth rate (CAGR) of 6.0%. This anticipated growth during the forecast period is largely due to factors such as the advancement of automated and robotic systems for compounding, the broadened availability of homecare chemotherapy services, increased funding for sterile pharmacy facilities, stricter regulatory adherence for individualized medicine, and the proliferation of targeted therapies and immunomodulatory agents. Key trends during the forecast period encompass a wider acceptance of customized chemotherapy formulations, the incorporation of robotic compounding technologies, an increase in compounding services offered in homecare and specialized clinics, a heightened emphasis on maintaining sterile and uncontaminated settings, and a greater need for compounding supportive care medications.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25724&type=smp
Which Market Drivers Are Supporting The Expansion Of The Compounding Chemotherapy Market?
The rising incidence of cancer diagnoses is projected to fuel the expansion of the compounding chemotherapy market in the future. Cancer is defined as a collection of illnesses marked by the unregulated proliferation and dissemination of atypical cells throughout the body. This increase in cancer diagnoses largely stems from unhealthy habits like inadequate nutrition, insufficient exercise, tobacco use, heavy drinking, and extended contact with environmental contaminants, all of which substantially elevate the chances of developing diverse forms of cancer. Compounding chemotherapy aids cancer therapy by allowing for customized drug preparations, specifically designed for each patient’s requirements, thereby enhancing effectiveness and reducing adverse reactions. As an illustration, in October 2025, data from the National Health Service (NHS), a government health agency in the UK, indicated 354,820 new cancer diagnoses in 2023, averaging 972 daily, a figure 8,605 higher than in 2022. Consequently, the growing occurrence of cancer instances propels the expansion of the compounding chemotherapy market.
What Segment Groups Are Identified Within The Compounding Chemotherapy Market?
The compounding chemotherapy market covered in this report is segmented –
1) By Drug Type: Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies, Supportive Care Drugs
2) By Route Of Administration: Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal
3) By Technology: With Robotic Arms, Without Robotic Arms
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By Compounding Setting: Hospital Compounding, Compounding Pharmacies, Specialty Clinics, Homecare Settings
Subsegments:
1) By Cytotoxic Drugs: Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, Topoisomerase Inhibitors
2) By Hormonal Agents: Estrogen Antagonists, Androgen Deprivation Therapy Agents, Aromatase Inhibitors, Progestins, Gonadotropin-Releasing Hormone Agonists
3) By Immunomodulatory Agents: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Interleukins, Cytokines, Immune System Activators
4) By Targeted Therapies: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Poly Polymerase Inhibitors
5) By Supportive Care Drugs: Antiemetics, Erythropoiesis-Stimulating Agents, Bone-Modifying Agents, Pain Management Drugs
What Trends Are Advancing Progress In The Compounding Chemotherapy Market?
Leading companies in the compounding chemotherapy market are concentrating their efforts on devising innovative solutions, specifically robotic chemotherapy automation systems, to improve precision, safety, and efficiency in the formulation of personalized cancer treatments. These robotic systems are sophisticated devices engineered to precisely and safely prepare customized chemotherapy dosages by automating the compounding process, thereby mitigating human errors and contamination risks. As an illustration, Simplivia Healthcare Ltd., an Israeli healthcare technology firm, unveiled its Smart Compounders Advanced Systems in February 2024. These systems are designed to automate and optimize the preparation of cytotoxic (chemotherapy) drugs, capable of compounding cytostatics and antibodies at a rate of 20 to 40 preparations per hour. They incorporate automatic gravimetric verification and documentation to guarantee exceptional accuracy. A key benefit is their significant reduction of pharmacy staff’s exposure to hazardous substances, and they are engineered for seamless integration into existing laminar airflow (LAF) cabinets or isolators without requiring any alterations.
Which Companies Hold Significant Positions In The Compounding Chemotherapy Market?
Major companies operating in the compounding chemotherapy market are Baxter International Inc., Fresenius Kabi AG, Option Care Health Inc., ICU Medical Inc., Fagron NV, BioScrip Inc., B. Braun Melsungen AG, Medisca Pharmaceutique Inc., Central Admixture Pharmacy Services Inc., Icon Group Holdings Pty Ltd, Avella Specialty Pharmacy, McGuff Compounding Pharmacy Services Inc., Epicur Pharma LLC, PharMEDium Services LLC.
Read the full compounding chemotherapy market report here:
https://www.thebusinessresearchcompany.com/report/compounding-chemotherapy-global-market-report
How Is The Compounding Chemotherapy Market Distributed Across Key Geographic Regions?
North America was the largest region in the compounding chemotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the compounding chemotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Compounding Chemotherapy Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25724&type=smp
Browse Through More Reports Similar to the Global Compounding Chemotherapy Market 2026, By The Business Research Company
Chemotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report
Oncology Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market
Oncology Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model